J&J's nipocalimab Sjögren's data show which symptoms patients most want improved
What's the deal? On 7 November 2026, Johnson & Johnson Innovative Medicine announced new patient-experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease, a chronic autoimmune condition in which the immune system attacks the body's moisture-producing glands, causing dry eyes and mouth, fatigue and joint pain. The data, drawn from structured interviews with study participants after their treatment period, are being presented at the American College of Rheumatology (ACR) 2026 meeting.
Why it matters: The findings map which symptoms patients with Sjögren's most want improved, information regulators and trial designers increasingly weight when assessing whether a treatment helps people live better. Of the symptoms patients reported most often, mouth dryness was the one they most wanted to see improve; it was reported by 96% of participants, followed by fatigue (92%), eye dryness (90%), joint pain (73%) and, among women, vaginal dryness (49%). Nipocalimab is an antibody designed to lower levels of IgG antibodies by blocking a recycling receptor (FcRn), an approach being studied across several autoimmune diseases. Two Phase 3 trials of nipocalimab in Sjögren's disease are ongoing, both including these patient-important measures.
Read more: Johnson & Johnson via PR Newswire, 07 November 2026